HARP — Harpoon Therapeutics Share News
0.000.00%
Last trade - 00:00- $492.35m
- $469.57m
- $31.92m
Brief: Harpoon Therapeutics Announces Up to $150 Mln Private Placement
Brief: Harpoon Therapeutics Announces Updated Interim Tolerability And Response Data From Phase 1/2 Clinical Trial Of T Cell Engager Hpn328
Brief: Harpoon Therapeutics Announces First Patients With Small Cell Lung Cancer Dosed In Hpn328 Combination Cohort
U.S. RESEARCH ROUNDUP-Hostess Brands, MetLife, Prudential Financial
Harpoon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Harpoon Therapeutics Q2 revenue USD 20.221 million
Harpoon Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Harpoon Therapeutics Announces Completion Of Planned Patient Enrollment In Early-Stage Blood Cancer Trial
Harpoon Therapeutics Inc rises on smaller-than-expected Q1 loss
Harpoon Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Harpoon Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
Harpoon Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Harpoon Therapeutics Files For Mixed Shelf Of Up To $250 Million
Brief: Harpoon Therapeutics Presents Data For New Protritac Development Candidates In TROP2- And ITGB6-Expressing Solid Tumors At AACR
Brief: Artal International S.C.A. Reports 6.1% Passive Stake In Harpoon Therapeutics Inc Common Stock As Of March 23, 2023
Brief: Harpoon Therapeutics Receives Notice Of Delisting From Nasdaq
U.S. RESEARCH ROUNDUP- Cintas, Stryker, Zimmer Biomet Holdings
Harpoon Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Harpoon Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview